Cyramza Interactions
There are 138 drugs known to interact with Cyramza (ramucirumab), along with 8 disease interactions. Of the total drug interactions, 100 are major, and 38 are moderate.
- View all 138 medications that may interact with Cyramza
- View Cyramza disease interactions (8)
Most frequently checked interactions
View interaction reports for Cyramza (ramucirumab) and the medicines listed below.
- Alimta (pemetrexed)
- Aloxi (palonosetron)
- Benadryl (diphenhydramine)
- bisacodyl
- Carafate (sucralfate)
- carboplatin
- Decadron (dexamethasone)
- dexamethasone
- fluorouracil
- folic acid
- Injectafer (ferric carboxymaltose)
- irinotecan
- Keytruda (pembrolizumab)
- Lasix (furosemide)
- levalbuterol
- levothyroxine
- lisinopril
- melatonin
- metformin
- metoprolol
- Metoprolol Tartrate (metoprolol)
- montelukast
- Norco (acetaminophen / hydrocodone)
- ondansetron
- oxaliplatin
- prednisone
- Taxol (paclitaxel)
- Taxotere (docetaxel)
- Vitamin B12 (cyanocobalamin)
- Zometa (zoledronic acid)
Cyramza disease interactions
There are 8 disease interactions with Cyramza (ramucirumab) which include:
- bleeding
- GI perforation
- hypothyroidism
- liver dysfunction
- hypertension
- PRES
- proteinuria
- thromboembolic disorders
More about Cyramza (ramucirumab)
- Cyramza consumer information
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: VEGF/VEGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.